Registration number: 08874152

Dr Albani Limited

Contents

Balance Sheet	1
Notes to the Unaudited Financial Statements	2 to 6

Dr Albani Limited

(Registration number: 08874152)
Balance Sheet as at 31 December 2024

	Note	2024 £	2023 £
Fixed assets
Intangible assets	4	31,877	36,928
Tangible assets	5	466	737
Other financial assets	6	87	-
		32,430	37,665
Current assets
Debtors	7	37,648	24,180
Cash at bank and in hand		5,589	24,269
		43,237	48,449
Creditors: Amounts falling due within one year	8	(251,488)	(201,842)
Net current liabilities		(208,251)	(153,393)
Net liabilities		(175,821)	(115,728)
Capital and reserves
Called up share capital		167	167
Share premium reserve		688,482	688,483
Retained earnings		(864,470)	(804,378)
Shareholders' deficit		(175,821)	(115,728)

For the financial year ending 31 December 2024 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

Directors' responsibilities:

•	The members have not required the company to obtain an audit of its accounts for the year in question in accordance with section 476; and
•	The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.

These financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime. As permitted by section 444 (5A) of the Companies Act 2006, the directors have not delivered to the registrar a copy of the Profit and Loss Account.

Approved and authorised by the Board on 17 December 2025 and signed on its behalf by:
 

......................................... O Albani Director

Dr Albani Limited

Notes to the Unaudited Financial Statements for the Year Ended 31 December 2024

1	General information

The company is a private company limited by share capital, incorporated in England & Wales.

The address of its registered office is:
5th Floor, North Side
7/10 Chandos Street
Cavendish Square
London
W1G 9DQ

2	Accounting policies

Summary of significant accounting policies and key accounting estimates

The principal accounting policies applied in the preparation of these financial statements are set out below. These policies have been consistently applied to all the years presented, unless otherwise stated.

Statement of compliance

These financial statements have been prepared in accordance with Financial Reporting Standard 102 Section 1A smaller entities - 'The Financial Reporting Standard applicable in the United Kingdom and Republic of Ireland' and the Companies Act 2006 (as applicable to companies subject to the small companies' regime).

Basis of preparation

These financial statements have been prepared using the historical cost convention except that as disclosed in the accounting policies certain items are shown at fair value.

The financial statements are presented in UK Sterling pounds (£).

Going concern

The financial statements have been prepared on a going concern basis, notwithstanding the net asset deficiency, on the basis that the company will be supported financially by the shareholder to enable the company to meet its financial liabilities as they fall due.

Revenue recognition

Turnover comprises the fair value of the consideration received or receivable for the sale of goods and provision of services in the ordinary course of the company’s activities. Turnover is shown net of sales/value added tax, returns, rebates and discounts.

The company recognises revenue when:
The amount of revenue can be reliably measured;
it is probable that future economic benefits will flow to the entity;
and specific criteria have been met for each of the company's activities.

Foreign currency transactions and balances

Transactions in foreign currencies are initially recorded at the functional currency rate prevailing at the date of the transaction. Monetary assets and liabilities denominated in foreign currencies are retranslated into the respective functional currency of the entity at the rates prevailing on the reporting period date. Non-monetary items carried at fair value that are denominated in foreign currencies are retranslated at the rate on the date when the fair value is re-measured.

Non-monetary items measured in terms of historical cost in a foreign currency are not retranslated.

Dr Albani Limited

Notes to the Unaudited Financial Statements for the Year Ended 31 December 2024

Tax

The tax expense for the period comprises current tax. Tax is recognised in profit or loss, except that a change attributable to an item of income or expense recognised as other comprehensive income is also recognised directly in other comprehensive income.

The current income tax charge is calculated on the basis of tax rates and laws that have been enacted or substantively enacted by the reporting date in the countries where the company operates and generates taxable income.

Tangible assets

Tangible assets are stated in the balance sheet at cost, less any subsequent accumulated depreciation and subsequent accumulated impairment losses.

The cost of tangible assets includes directly attributable incremental costs incurred in their acquisition and installation.

Depreciation

Depreciation is charged so as to write off the cost of assets, other than land and properties under construction over their estimated useful lives, as follows:

Asset class	Depreciation method and rate
Plant and machinery	20% Straight line
Office equipment	20% Straight line

Intangible assets

Separately acquired trademarks and licences are shown at historical cost.

Trademarks, licences (including software) and customer-related intangible assets acquired in a business combination are recognised at fair value at the acquisition date.

Trademarks, licences and customer-related intangible assets have a finite useful life and are carried at cost less accumulated amortisation and any accumulated impairment losses.

Development costs

Development costs such as the design, construction and testing of pre-production or pre-use prototypes and models are written off as they are incurred

Amortisation

Amortisation is provided on intangible assets so as to write off the cost, less any estimated residual value, over their useful life as follows:

Asset class	Amortisation method and rate
Patent	Over 15 years straight line

Cash and cash equivalents

Cash and cash equivalents comprise cash on hand and call deposits, and other short-term highly liquid investments that are readily convertible to a known amount of cash and are subject to an insignificant risk of change in value.

Dr Albani Limited

Notes to the Unaudited Financial Statements for the Year Ended 31 December 2024

Trade debtors

Trade debtors are amounts due from customers for merchandise sold or services performed in the ordinary course of business.

Trade debtors are recognised initially at the transaction price. They are subsequently measured at amortised cost using the effective interest method, less provision for impairment. A provision for the impairment of trade debtors is established when there is objective evidence that the company will not be able to collect all amounts due according to the original terms of the receivables.

Trade creditors

Trade creditors are obligations to pay for goods or services that have been acquired in the ordinary course of business from suppliers. Accounts payable are classified as current liabilities if the company does not have an unconditional right, at the end of the reporting period, to defer settlement of the creditor for at least twelve months after the reporting date. If there is an unconditional right to defer settlement for at least twelve months after the reporting date, they are presented as non-current liabilities.

Trade creditors are recognised initially at the transaction price and subsequently measured at amortised cost using the effective interest method.

3	Staff numbers

The average number of persons employed by the company (including directors) during the year, was 2 (2023 - 2).

4	Intangible assets

	Trademarks, patents and licenses  £	Total £
Cost or valuation
At 1 January 2024	76,517	76,517
At 31 December 2024	76,517	76,517
Amortisation
At 1 January 2024	39,589	39,589
Amortisation charge	5,051	5,051
At 31 December 2024	44,640	44,640
Carrying amount
At 31 December 2024	31,877	31,877
At 31 December 2023	36,928	36,928

The aggregate amount of development expenditure recognised as an expense during the period is £(90,690) (2023 - £153,630).
 

Dr Albani Limited

Notes to the Unaudited Financial Statements for the Year Ended 31 December 2024

5	Tangible assets

	Office equipment £	Other tangible assets  £	Total £
Cost or valuation
At 1 January 2024	5,013	10,350	15,363
At 31 December 2024	5,013	10,350	15,363
Depreciation
At 1 January 2024	4,276	10,350	14,626
Charge for the year	271	-	271
At 31 December 2024	4,547	10,350	14,897
Carrying amount
At 31 December 2024	466	-	466
At 31 December 2023	737	-	737

6	Other financial assets (current and non-current)

	Financial assets at cost less impairment £	Total £
Non-current financial assets
Cost or valuation
Additions	87	87
At 31 December 2024	87	87
Impairment
Carrying amount
At 31 December 2024	87	87

Dr Albani Limited

Notes to the Unaudited Financial Statements for the Year Ended 31 December 2024

7

Debtors

Current	Note	2024 £	2023 £
Trade debtors		4,931	-
Amounts owed by related parties	10	6,967	-
Prepayments		3,651	106
Other debtors		22,099	24,074
		37,648	24,180

8

Creditors

Creditors: amounts falling due within one year

	2024 £	2023 £
Due within one year
Trade creditors	10,490	110,297
Accruals and deferred income	13,997	15,817
Other creditors	227,001	75,728
	251,488	201,842

9	Contingent assets: R&D Tax Credit

The Company will submit a claim for Research and Development (R&D) tax credits with HM Revenue & Customs (HMRC) for the accounting period ended 31 December 2024.
The potential inflow of economic benefits is estimated to be approximately £4,405.00, measured in accordance with the relevant accounting standards.
The Directors are of the opinion, based on advice from the Company's R&D tax advisers, that it is probable that the claim will be successful and the funds received.
However, as the final outcome and timing of the settlement remain subject to HMRC's formal approval and review procedures, the potential asset has not been recognised in the Statement of Financial Position at the reporting date.

10	Related party transactions

Summary of transactions with other related parties

Other creditors include a shareholder's loan of £205,000 (2023 - £74,534). The loan has an interest to pay at a rate of 10% per annum. The interest is calculated on daily basis and shall be payable quarterly, annually in arrears.